POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
Pomdoctor (Nasdaq: POM) announced that on July 10, 2026 it received a Nasdaq Compliance Letter confirming it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1).
Rhea-AI Summary
Pomdoctor (Nasdaq: POM) announced that on July 10, 2026 it received a Nasdaq Compliance Letter confirming it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1). Nasdaq determined that from June 25 to July 9, 2026 Pomdoctor’s ADSs closed at or above $1.00 for 10 consecutive business days, closing the matter. The company’s American Depositary Shares will continue trading on Nasdaq under the ticker symbol POM.
Positive
- Regained Nasdaq compliance with $1.00 minimum bid price under Rule 5450(a)(1)
- 10 consecutive business days with closing bid at or above $1.00 (June 25–July 9, 2026)
- Nasdaq matter closed; ADSs continue listing under ticker POM
Negative
- None.
News Explained
The Nasdaq listing deficiency is closed, and POM’s ADS remain listed after meeting the required bid-price test.
On
The deficiency followed 30 consecutive business days below
Details
Market move: POM -7.19% in the Jul 13 session. Nasdaq bid-price compliance update
On Jul 13, the day this news came out, POM closed 7.19% below the previous close. Argus tracked a trough of -10.0% from its starting point during tracking. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 13 session.
Key Figures
- Nasdaq minimum bid
- $1.00 per share
- Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement
- Non-compliance period
- 30 consecutive business days
- Closing bid below $1.00 per ADS before deficiency notice
- Compliance period
- 10 consecutive business days
- Closing bid at or above $1.00 per ADS from June 25–July 9, 2026
- Deficiency notice date
- January 29, 2026
- Nasdaq notification of bid price non-compliance
- Compliance letter date
- July 10, 2026
- Nasdaq confirmed Pomdoctor regained bid price compliance
Historical Context
-
Outlined progress on AI-enabled chronic disease management and predictive ecosystem.
-
Announced repositioning as predictive healthcare data infrastructure provider.
-
Implemented one-for-eighteen reverse ADS split via ratio change.
-
Planned one-for-eighteen reverse ADS split subject to filing effectiveness.
-
Reported revenue growth alongside wider net loss and higher expenses.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5450(a)(1) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
As previously disclosed, on January 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company's American Depositary Shares had been below
With Nasdaq's confirmation of compliance, Pomdoctor American Depositary Shares will continue to be listed on Nasdaq under the ticker symbol "POM."
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-regains-compliance-with-nasdaq-bid-price-requirement-302823751.html
SOURCE POMDOCTOR LIMITED
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.